The deal could be a big win for Seattle Genetics, but it doesn’t have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC — the beneficial owner of 9.9% of Immunomedics shares — said Immunomedics’ board of directors is “giving away its crown jewel.”